EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt

This publication has 46 references indexed in Scilit:

• ERBB receptors and cancer: the complexity of targeted inhibitors
  Nature Reviews Cancer, 2005
• Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities
  European Urology, 2005
• Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
  Journal of Clinical Oncology, 2005
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
  Cancer Cell, 2004
• Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation Therapy
  European Urology, 2004
• Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype
  Journal of Cellular Biochemistry, 2004
• Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
  The Prostate, 2002
• Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells
  Molecular and Cellular Biology, 2001
• Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms
  Biochemical Journal, 2001
• The ErbB signaling network: receptor heterodimerization in development and cancer
  The EMBO Journal, 2000